ROCALTROL (calcitriol) by AbbVie is clinical pharmacology man's natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin d 3 (cholecalciferol). First approved in 1998.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
ROCALTROL (calcitriol) is the active form of vitamin D3, a hormone that regulates calcium and phosphorus metabolism. It is indicated for patients with renal failure who cannot adequately synthesize calcitriol endogenously, treating hypocalcemia and secondary hyperparathyroidism. The drug works by binding to calcitriol receptors in the intestine and bone to stimulate calcium absorption and correct metabolic bone disease.
Product is in late-stage lifecycle with modest utilization (239 claims in 2023), indicating a mature, stable franchise with limited growth potential and likely smaller commercial teams.
CLINICAL PHARMACOLOGY Man's natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D 3 (cholecalciferol). Vitamin D 3 must be metabolically activated in the liver and the kidney before it is fully…
Worked on ROCALTROL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Vitamin D3 Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
Oral Calcitriol With Ketoconazole in CRPC
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ROCALTROL offers limited career growth due to its mature lifecycle and approaching loss of exclusivity. Roles focus on maximizing reimbursement, defending market share against generics, and maintaining physician relationships rather than driving innovation or expansion.